Previous Page  19 / 39 Next Page
Information
Show Menu
Previous Page 19 / 39 Next Page
Page Background

conferenceseries

.com

Page 50

Notes:

Volume 7, Issue 6 (Suppl)

J Biotechnol Biomater, an open access journal

ISSN: 2155-952X

World Biotechnology 2017

December 04-05, 2017

2

nd

World Biotechnology Congress

December 04-05, 2017 | Sao Paulo, Brazil

iPS-derived cardiomyocytes and keratinocytes for drug screening and cytotoxicity assays

Estela M Cruvinel

Pluricell Biotech, Brazil

I

nduced pluripotent stem cells (iPSC) are promising tool for disease modeling, regenerative medicine and drug screening. Pluricell

Biotech is a Brazilian startup that develops

in vitro

iPS-derived models. Currently, we have established a highly efficient 2D

differentiation protocol to obtain iPSC-derived cardiomyocytes. After 30 days of differentiation, PluriCardio can be replated in 2D

monolayers or 3D spheroids. More than 70% of our differentiations have 95% or more of purity seen through positive expression

of cardiac specific markers. Different cardiomyocytes subtypes are observed depending on how cells are plated, when in monolayer,

75% of the cells have a ventricular phenotype after 15 days of culture, and 97% have ventricular phenotype in 3D plating. We show

electrophysiological response to classical drugs as expected, we checked responses to beta-adrenergic, calcium, sodium, potassium

receptors including the verification of the well know hERG/IK potassium receptor. These cardiomyocytes were also used the evaluate

doxorrubicin toxicity, we show they are affected by this drug. Taken together, these data suggest that our cardiomyocytes are a good and

reliable tool for cardiac research and drug screening. Our future direction is to develop a platform with iPS-derived cardiomyocytes

is to create a score of cardiotoxicity based and combined evaluation of different cardiotoxicity assays. We also established an efficient

keratinocyte differentiation protocol. To date, we obtained 90% of K14-positive cells. iPS-derived keratinocytes expressed some

keratinocyte markers as K14, K5, ITGa6, ITGb4, deltaNp63. After 7 days, exposed to a high concentration of calcium medium some

cells expressed K10 and involucrin. Our future direction with iPS-derived keratinocytes is to evaluate their potential to grown in 3D

model and evaluated their answers in cytotoxicity analyses.

Biography

Estela M Cruvinel has her expertise in cell culture and human genetics. She is Researcher at Pluricell Biotech, a Brazilian startup that develops

in vitro

iPS-derived models.

She believes that iPS-derived cells are powerful tools for basic science and clinical applications. iPS-derived cells can be important for disease modeling. She has worked

with these cells in her PhD to study genomic imprinting in Prader-Willi and Angelman syndromes. Moreover, their use in drug screening and cytotoxicity assays are valuable

because they are able to replace or reduce the use of some animal models or animal cells. Currently, she coordinates the project that establishes iPS cells differentiation

into keratinocytes.

estela.cruvinel@pluricellbiotech.com

Estela M Cruvinel, J Biotechnol Biomater 2017, 7:6 (Suppl)

DOI: 10.4172/2155-952X-C1-085